BASEL, SWITZERLAND--(Marketwire - May 25, 2012) -
Basilea Pharmaceutica AG /
Basilea participates in public-private collaboration to tackle antibiotic
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Basilea Pharmaceutica Ltd. welcomes the
launch in Europe of a pioneering approach to antibiotic research that will
pharmaceutical and biotechnology companies working alongside public
tackle the rising threat from antimicrobial resistance and address some of
key barriers to the development of effective antibiotics.
The objective of the proposed research program, NewDrugs4BadBugs, is to
the underlying scientific understanding of antibiotic resistance, design
implement efficient clinical trials and take novel drug candidates through
clinical development. The program is part of the European Commission's
Plan against the rising threats from Antimicrobial Resistance, launched in
November last year.
Supported by the Innovative Medicines Initiative (IMI), the world's largest
public-private partnership in health care, the program's first projects
funded by a joint budget of up to EUR 223.7 million - EUR 109 million
by IMI and EUR 114.7 million in kind contributions from the pharmaceutical
biotechnology companies involved.
Basilea, GlaxoSmithKline, AstraZeneca, Janssen and Sanofi will work
public research organizations and scientific experts to address several
of antimicrobial resistance and stimulate new antibiotic research. Further
projects within the program, with additional funding, are expected to
later in the year.
Basilea's Chief Scientific Officer, Dr. Laurenz Kellenberger, stated:
"Antibiotic R&D is at an important turning point. We have joined this
collaboration because of our strong belief in its significant value to all
stakeholders concerned with fighting antimicrobial drug resistance. The
scientific and financial advantages of the initiative will contribute to
increasing the chances of finding new effective antimicrobial drugs.
with ongoing positive developments in the regulatory and legislative areas
see the environment becoming even more attractive and rewarding for small
Antibiotic resistance is increasingly becoming a worldwide health threat.
of the medical advances in recent years, such as chemotherapy for cancer
treatment and organ transplantation, depend on effective antibiotics.
this need and the continued emergence of bacteria resistant to existing
research has diminished over the past 15 years and few companies remain
in this area. This is due to the scientific difficulties in finding new
that successfully target bacteria, regulatory complexities and insufficient
commercial incentives needed to encourage investment in this area and to
The proposed research program will initially focus on three key areas:
progressing development of pipeline antibiotics and improving the design of
future clinical trials; information sharing across the wider antibiotic
community to improve the chances of success in developing the next
antibiotics; and continuing research and discovery of new antibiotics,
specifically finding new approaches to the design of antibiotics effective
against Gram-negative bacteria.
Key to the success of NewDrugs4BadBugs will be the involvement of multiple
public partners from across Europe. Public institutions and research
organizations, clinical investigators and scientific experts are being
encouraged to learn more about the proposed research program through a
events. Full details can be found at www.imi.europa.eu.
Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and
the SIX Swiss Exchange (SIX: BSLN). Through its fully integrated research
development operations the company focuses on innovative pharmaceutical
in the therapeutic areas of bacterial infections, fungal infections,
and skin diseases, targeting the medical challenge of rising resistance and
non-response to current treatment options in the hospital and specialty
Basilea's portfolio of investigational anti-infectives includes
isavuconazole and BAL30072.
Ceftobiprole is a novel broad-spectrum anti-MRSA cephalosporin antibiotic
the potential first-line empiric treatment of severe multi-drug resistant
bacterial infections. Available data demonstrate activity against a wide
of clinically-relevant Gram-positive as well as Gram-negative bacteria
Pseudomonas, highlighting the potential of ceftobiprole for the early
of severe infections such as pneumonia treated in the hospital.
Isavuconazole is a novel broad-spectrum antifungal with the potential to
the best-in-class azole for the treatment of severe invasive fungal
It has excellent in-vitro and in-vivo coverage of a broad range of yeasts
as Candida species) and molds (such as Aspergillus species) as well as less
common but clinically important molds such as Zygomycetes spp.
BAL30072 is a novel sulfactam antibiotic specifically targeting
multidrug-resistant Gram-negative bacteria. In in-vitro and in-vivo models
potent bactericidal activity against a broad range of multidrug-resistant
Gram-negative pathogens such as Pseudomonas or Acinetobacter species. It
bacterial resistance by several mechanisms and has enhanced stability
bacterial beta-lactamase enzymes, such as extended-spectrum beta-lactamases
(ESBLs), carbapenemases and the recently characterized New Delhi
metallo-beta-lactamase 1 (NDM-1), which cause resistance against many
antibiotics. The activity of BAL30072 is further enhanced when combined
About the Innovative Medicines Initiative (IMI)
The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a unique
pan-European public private partnership between the European Commission and
(European Federation of Pharmaceutical Industries and Associations). The
IMI is to propose a coordinated approach to overcome identified research
bottlenecks in the drug development process, in order to accelerate the
development of safe and more effective medicines for patients, by fostering
collaboration between all stakeholders such as industry, public authorities
(including regulators), organizations of patients, academia and clinical
centers, and enhancing Europe's competitiveness. Further information can be
found at www.imi.europa.eu.
This communication expressly or implicitly contains certain forward-looking
statements concerning Basilea Pharmaceutica Ltd. and its business. Such
statements involve certain known and unknown risks, uncertainties and other
factors, which could cause the actual results, financial condition,
or achievements of Basilea Pharmaceutica Ltd. to be materially different
any future, anticipated results, performance or achievements expressed or
implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is
providing this communication as of this date and does not undertake to
any forward-looking statements contained herein as a result of new
future events or otherwise.
This press release can be downloaded from www.basilea.com.
Press release (PDF):
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Basilea Pharmaceutica AG via Thomson Reuters ONE